Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2025)

Barinthus Biotherapeutics' Total Non-Current Liabilities history spans 5 years, with the latest figure at $22.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 22.31% year-over-year to $22.4 million; the TTM value through Dec 2025 reached $22.4 million, down 22.31%, while the annual FY2025 figure was $22.4 million, 22.31% down from the prior year.
  • Total Non-Current Liabilities reached $22.4 million in Q4 2025 per BRNS's latest filing, down from $23.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $32.6 million in Q3 2023 to a low of $22.4 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $27.2 million, with a median of $26.5 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: grew 10.1% in 2024, then dropped 22.31% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $25.8 million in 2021, then dropped by 1.9% to $25.3 million in 2022, then rose by 3.53% to $26.2 million in 2023, then rose by 10.1% to $28.8 million in 2024, then fell by 22.31% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Total Non-Current Liabilities are $22.4 million (Q4 2025), $23.2 million (Q3 2025), and $25.6 million (Q2 2025).